

ExpertFORUM Pharmacovigilance 2018

The latest information | Social event in a unique atmosphere | Top speakers

Two days of intensive talks by and for drug safety experts!

What to expect:

- Latest PV news
- New impulses for your work
- I High-level discussion with colleagues and experts

Your topics

- IDMP and SPOR: Consequences for pharmacovigilance
- Data protection: The new EU regulation and initial experiences
- Harmonisation of RMP by CMDh
- EudraVigilance and signal management
- Brexit countdown
- Mergers and acquisitions: A drug safety perspective
- Inspection readiness: An authority's perspective
- Liability issues in pharmacovigilance
- And much more

12 – 13 November 2018 in Frankfurt

Your programme on 12 November Chair: Prof Burkhard Sträter

Prof Burkhard Sträter Sträter Lawers, Bonn, Germany



Dr Norbert Paeschke - requested -Senior Expert Pharmacovigilance, Bonn, Germany

Dr Melanie Ruppel **Boehringer Ingelheim International** GmbH, Ingelheim, Germany

Head of Global Submission Services Ingelheim



Epidemiologist, Senior Assessor Pharmacovigilance



Welcome and introduction





11:00

IDMP and SPOR: Impact on pharmacovigilance

- EMA master data management roadmap
- IDMP and SPOR concept
- Consequences for pharmacovigilance

12:00 Coffee break

12.15

Harmonisation of RMP by CMDh

13:15

Discussion: Consequences of regulatory developments for the pharmaceutical industry

13:40 Lunch

14:45

Inspection readiness – an authority's perspective

- Current priorities of PV inspectors
- Typical findings in a changing regulatory environment

15:30



Bonn, Germany

Dr Kimberley Sherwood Senior Expert Pharmacovigilance,

Bonn, Germany

Partner

Horst Kastrup Senior Regulatory Expert, Muenster, Germany

and



Head of Commercial & Partner Management



16:00 Coffee break 16:15

Impact of pharmacovigilance on early benefit assessment

Looking beyond the horizon: Falsified Medicines Directive, February 2019 deadline

- Falsified Medicines Directive 2011/62/EU (FMD)
- Current state of implementation
- Link to IDMP and SPOR

(§ 35a SGB V)

- Risks due to falsified medicinal products
- Impact of the FMD on pharmacovigilance
 - Role of pharmacovigilance in the anti-counterfeit company project
- Are today's processes appropriate for controlling the risks due to falsified and diverted medicines?

18:00 End of Day 1

18:30 Evening event





Your programme on 13 November Chair: Dr Tanja Peters

09:00 Welcome and introduction

09:15

BREXIT Countdown -

Q&A with a focus on Pharmacovigilance

- State of Brexit negotiations and timelines
- Impact and challenges for Pharmacovigilance
- Q&A with the attendees

10:00

Data privacy - The new EU regulation

- What's new and what are the major challenges?
- Challenges for pharmacovigilance

11:00 Coffee break

11:20

Mergers and acquisitions: A pharmacovigilance perspective

12:00

Pharmacovigilance System Master File (PSMF) – Partner Audits

12:45 Lunch

14:00

Workshop: The role of the safety department in clinical development – service provider or development partner?



Liability Issues in Pharmacovigilance and Safety Referral Procedures

- Offenses and civil liability
- Referral procedures and liability implications
- Relevance of PV inspections and PV audits
- Who can be personally liable: National PV Officer, QPPV, Managing Director, PV employees?
- Protection against liability cases and insurance questions

15:45 Final Q&A session

16:00 End of conference



Dr Tanja Peters Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany

Head PV Intelligence & Deputy EU-QPPV



Dr Dr Adem Koyuncu Law firm Covington & Burling LLP

Partner in the Brussels and Frankfurt offices, Lawyer and Medical Doctor. Licensed to practice in Brussels and Germany



Daniela Fábián Masoch FABIAN PRIVACY LEGAL GmbH, Basel, Switzerland

Attorney at Law & Privacy Professional



Dr Tanja Peters Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany

Head PV Intelligence & Deputy EU-QPPV



Dr Monika Manske Mylan Healthcare GmbH, Hannover, Germany

Lead Quality Management Pharmacovigilance Safety & Risk Management



Dr Reinhard Fescharek CSL Behring GmbH, Marburg, Germany

Senior Advisor to the Chief Medical Officer



Dr Dr Adem Koyuncu Law firm Covington & Burling LLP

Partner in the Brussels and Frankfurt offices, Lawyer and Medical Doctor. Licensed to practice in Brussels and Germany

Aims and objectives

FORUM Institut and the conference chairs are pleased to welcome you to this year's ExpertFORUM Pharmacovigilance.

This conference has become a jour fixe for drug safety departments in the pharmaceutical industry. As always, we will highlight the latest regulatory developments and their implications for the pharmaceutical industry, and provide concrete suggestions for your daily work. We will also provide the latest information on current pharmacovigilance issues.

I look forward to meeting you personally in Frankfurt.

Kind regards,

· Jegodlea



Jessica Jegodka

Conference Manager Pharma & Healthcare Tel. +49 6221 500-696 j.jegodka@forum-institut.de

Who should attend

The conference is primarily intended for drug safety managers, local drug safety representatives and QPPVs needing to be informed about current regulatory developments and operational implementation issues.

It is also aimed at senior executives at public authorities and research institutions, and in:

- Medical Affairs;
- Regulatory Affairs;
- Clinical Research; and
- Quality assurance

Your benefits

- Intensive discussion with pharmacovigilance leaders and authorities.
- Relevant expertise, including practical examples and projects.
- Sufficient time to address related issues.

Registration: +49 6221 500 555 or email: service@forum-institut.de

Yes, I will attend the

- □ ExpertFORUM Pharmacovigilance 2018
- Yes, i agree that FORUM Institut may inform me about events by: □ email; and/or □ telephone. I may withdraw my consent at any time

Name		
Position/Department		
Company		
Street address	 	
Postal Code/City/Country		
Tel. No.		
E-Mail	 	
Contact person at the office		

Date/Signature

Registration: +49 6221 500-500
Conference-No. 18 11 201

Date/Venue:

12 – 13 November 2018 in Frankfurt Le Méridien Parkhotel Wiesenhüttenplatz 28-38 · 60329 Frankfurt Tel. +49 69 2697-0 · Fax +49 69 2697-812

Fee:

€ 1,790.00 (+ German VAT) The fee includes course documentation (incl. free download) as well as midsession refreshments, lunch, evening event and certificate. Invoice and confirmation will be forwarded to you.

Cancellation Policy:

Our general terms and conditions apply (as of 01.01.2016) and are available upon request. We can send them to you anytime or you can find them on the internet at www.forum-institut.com/t&c

FORUM · Institut für Management GmbH · Postfach 10 50 60 · 69040 Heidelberg Tel. +49 6221 500-500 · Fax +49 6221 500-555 · www.forum-institut.de